Harbour Biomed gives Hong Kong new IPO dose

By Jonathan Breen
30 Nov 2020

China's Harbour Biomed, a clinical-stage biopharmaceutical company, has hit the road for its up to HK$1.8bn ($230.4m) listing.

The issuer, floating in Hong Kong through HBM Holdings, was founded in 2016 for the discovery and development of antibody therapies for immunology and oncology.

The listing sponsors Bank of America, CLSA and Morgan Stanley began taking orders for the IPO on Monday, working alongside global co-ordinators CICC ...

Already a subscriber?

Continue reading this article

Try full access to GlobalCapital

Free trial